Isopropylphenidate
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
Isopropylphenidate (also known as IPH and IPPD) is a
Temporary Class Drug from April 2015 following its unapproved sale as a designer drug.[3]
It has been researched as potential methylphenidate replacement for
See also
References
- PMID 24261661.
- ^ a b US application 20120245201, Markowitz JS, Patrick KS, Zhu H, "Isopropylphenidate for Treatment of Attention-Deficit/Hyperactivity Disorder and Fatigue-Related Disorders and Conditions", published 2012-09-27
- ^ "Methylphenidate-based NPS: A review of the evidence of use and harm" (PDF). Advisory Council on the Misuse of Drugs. 31 March 2015.
- ^ Florence Levy (July 2014). "Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder". Pharmgenomics Pers Med: 349–356.